Online citations, reference lists, and bibliographies.
← Back to Search

[Immune-related Adverse Events Induced By ICIs In Advanced NSCLC: A Meta-analysis And Systematic Review].

Qiaoxi Qin, J. Wang, H. Wang
Published 2020 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
BACKGROUND In recent years, immune checkpoint inhibitors (ICIs) have become a hot spot in cancer because of their remarkable survival benefits on non-small cell lung cancer (NSCLC) patients. However, the immune-related adverse events (ir-AEs) induced by ICIs have been frequently reported due to its specificity and severity. This article is to summarize and evaluate ir-AEs induced by ICIs. Hopefully it can provide guidance for advanced NSCLC patients treatment options, early recognition and management of ir-AEs. METHODS Randomized controlled trials (RCT) which involved ICIs in the treatment of advanced NSCLC were retrieved in the Cochrane Libraby, PubMed, EMBASE and other databases. The primary outcome includes the incidence, grade and organ specificity of ir-AEs. Relative risk (RR) was used as the effect size, which was expressed as 95% confidence interval (CI). The Stata 15.0 and RevMan 5.3 software are used to conduct the meta analysis. RESULTS A total of 17 RCTs were included. The ir-AEs were generally more than those in the traditional chemotherapy group. The risk and severity of ir-AEs induced by ICIs combined group were generally higher than that of ICI monotherapy, while the incidence of severe ir-AEs induced by ICIs combination therapy was similar to that of anti-CTLA-4 group. CONCLUSIONS ICIs have different toxicity profile compared with chemotherapy, and their immune-related toxicity is stronger than that of traditional chemotherapy. ICIs induced ir-AEs is organ-specific, and different ICI has specific immune-related toxicity profiles. As ICIs represent a new and distinct class of treatment for NSCLC, this article has systematically illustrated the efficacy and ir-AEs induced by ICIs, hopefully it can be useful for clinicians and patients to get a further understanding of ICIs, and facilitate early prediction, comprehensive diagnosis, and prompt management of ir-AEs by providing status reference and management suggestions, so that ICI can bring more benefit for advanced NSCLC patients.
This paper references
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
Ayelet Sivan (2015)
Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials.
J. Wolchok (2010)
Moving Immune Checkpoint Blockade in Thoracic Tumors beyond NSCLC
F. Facchinetti (2016)
Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms
Danae A Delivanis (2017)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
H. Borghaei (2015)
Durvalumab after chemoradiotherapy in stage III non-small cell lung cancer.
P. Tomasini (2018)
Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer
J. C. Osorio (2017)
Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study.
S. Antonia (2016)
A genome-wide association study of myasthenia gravis.
A. Renton (2015)
Yervoy ( Ipilimumab ) , immune - mediated adverse reaction management guide
JS Weber (2011)
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.
C. Langer (2016)
Cancer statistics
N. Dubrawsky (1989)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
R. Herbst (2016)
Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer.
R. Govindan (2017)
Patterns of onset and resolution of immune‐related adverse events of special interest with ipilimumab
J. Weber (2013)
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center.
Troy Z. Horvat (2015)
Diagnosis and Management of Hepatitis in Patients on Checkpoint Blockade
K. Reynolds (2018)
Anti-CTLA4 Antibody-Induced Lupus Nephritis
V. Sepe (2009)
Management of immunerelated adverse events in patients treated with immune checkpoint inhibitor therapy: american society of clinical oncology clinical practice guideline
J R Brahmer (2018)
First-Line Nivolumab in Stage IV or Recurrent Non-Small Cell Lung Cancer
D. Carbone (2017)
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.
Matthew D. Hellmann (2019)
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
L. Fehrenbacher (2016)
Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study.
F. Barlési (2018)
Neurological immune-related adverse events of ipilimumab
I. Bot (2013)
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.
S. Topalian (2014)
Ipilimumab and Nivolumab induced steroid-refractory colitis treated with infliximab: A case report
Ammar Nassri (2019)
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
A. Menzies (2017)
Cytotoxic T-Lymphocyte-Associated Antigen 4 Antibody-Induced Colitis and Its Management with Infliximab
R. Johnston (2008)
Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study
A. Tsao (2012)
Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial
Y. Wu (2019)
The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification.
W. Travis (2015)
Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade
Stephanie G Downey (2007)
Faculty Opinions recommendation of The 2015 world health organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification.
P. Schil (2017)
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
M. Vétizou (2015)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
M. Reck (2016)
Targeting T Cell Co-receptors for Cancer Therapy.
M. Callahan (2016)
Anti–PD-1 Inhibitor–Related Pneumonitis in Non–Small Cell Lung Cancer
M. Nishino (2016)
Ipilimumab), immune-mediated adverse reaction management guide
S Bristol-Myers (2011)
Immunotherapy comes of age in octagenarian and nonagenarian metastatic melanoma patients.
Guy Ben-Betzalel (2019)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
J. Brahmer (2015)
Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer
L. Gandhi (2018)
Vitiligo in a case of vaccinia virus‐treated melanoma
K. Burdick (1964)
Immune-related Adverse Events Induced by ICIs in Advanced NSCLC: A Meta-analysis and Systematic Review
Q X Qin
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
A. Rittmeyer (2017)
Pembrolizumab plus Chemotherapy for Squamous Non–Small‐Cell Lung Cancer
L. Paz-Ares (2018)
Cancer statistics, 2019
R. Siegel (2019)
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
T. Mok (2019)

Semantic Scholar Logo Some data provided by SemanticScholar